Shots:

• The P-II AMBER2 study assessing the efficacy and safety of SHR0302 (8mg qd/4mg bid/4mg qd) vs PBO in 164 adults with moderate to severe UC across 84 sites in China- US- and EU. The AMBER2 study consisted of an 8wks. induction period- followed by an 8wks. extension period
• The study met its 1EPs i.e. percentage of patients who achieved a clinical response per the 9-point Mayo Score (46.3%/46.3%/43.9% vs 26.8%) @8wks.- improvement in patients (22%/24.4%/24.4 vs 4.9%) respectively
• SHR0302 is a potent and highly selective JAK1 inhibitor. The company expects to initiate the P-III program in 2021

 ­ Ref: PRNewswire | Image: PRNewswire